| ATC code J: Antiinfectives for systemic use |
|---|
|
| Human only |
| ATCvet only |
|
| Other ATC codes |
ATC code J02 Antimycotics for systemic use is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup J02 is part of the anatomical group J Antiinfectives for systemic use.[4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QJ02.[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
J02A Antimycotics for systemic use[edit]
J02AA Antibiotics[edit]
- J02AA01 Amphotericin B
- J02AA02 Hachimycin
J02AB Imidazole derivatives[edit]
- J02AB01 Miconazole
- J02AB02 Ketoconazole
- QJ02AB90 Clotrimazole
J02AC Triazole and tetrazole derivatives[edit]
- J02AC01 Fluconazole
- J02AC02 Itraconazole
- J02AC03 Voriconazole
- J02AC04 Posaconazole
- J02AC05 Isavuconazole
- J02AC06 Oteseconazole
J02AX Other antimycotics for systemic use[edit]
- J02AX01 Flucytosine
- J02AX04 Caspofungin
- J02AX05 Micafungin
- J02AX06 Anidulafungin
- J02AX07 Ibrexafungerp
- J02AX08 Rezafungin acetate
References[edit]
- ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- ^ "ATC/DDD Index 2022: code J02". WHO Collaborating Centre for Drug Statistics Methodology.
- ^ "ATCvet Index 2022: code QJ02". WHO Collaborating Centre for Drug Statistics Methodology.